Physician profile
Durwin D Walker
NPI 1316985898
$16,251.66
in general payments reported to CMS, 2019-2025
56 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,725 · 2020: $2,457 · 2021: $2,988 · 2022: $2,304 · 2023: $1,687 · 2024: $1,981 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,777.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,369.28 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,985.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $1,350.59 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,285.37 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,247.88 | 2019-2024 | Jardiance, Tradjenta, Spiriva Respimat |
| Pfizer INC. | $1,160.08 | 2019-2025 | |
| Novo Nordisk INC | $957.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $658.44 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $567.77 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $476.78 | 2019-2023 | Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $314.06 | 2022-2025 | |
| Axsome Therapeutics, INC. | $298.40 | 2024-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $281.19 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $257.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $250.88 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Durwin Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.